Retatrutide

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Retatrutide?

If your query is what is retatrutide, the practical answer is: retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist — a single molecule that activates GLP-1, GIP, and glucagon receptors simultaneously. It represents the most aggressive multi-receptor approach to obesity and metabolic disease currently in clinical development, and its Phase 2 trial results (published in the New England Journal of Medicine) produced the largest weight reductions ever reported for any anti-obesity medication.[1][2]

Retatrutide was developed by Eli Lilly (the same company behind tirzepatide). While tirzepatide is a dual GIP/GLP-1 agonist, retatrutide adds glucagon receptor activation as a third mechanism — introducing direct metabolic effects including increased energy expenditure, enhanced hepatic fat oxidation, and thermogenesis that go beyond appetite suppression alone.[2][7]

The compound is currently in Phase 3 clinical trials (the TRIUMPH programme) across multiple indications: obesity, type 2 diabetes, obstructive sleep apnoea, and knee osteoarthritis. No GLP-1-class compound has entered Phase 3 with such strong weight loss signals from earlier-phase data.[1][6]

Compound Profile

What Does Retatrutide Actually Do?

Retatrutide produces weight loss and metabolic improvement through coordinated activation of three hormone receptors. The Phase 2 clinical results are unprecedented in the obesity pharmacotherapy field:[1][2]

• Weight loss (Phase 2, obesity): Jastreboff et al. (2023) demonstrated up to 24.2% mean body weight reduction at 48 weeks with retatrutide 12 mg in adults with obesity — the largest weight loss ever reported for any anti-obesity medication in a controlled trial. Published in the New England Journal of Medicine.[1]
• Weight loss in T2D: Rosenstock et al. (2023) showed retatrutide produced up to 16.9% body weight loss in patients with type 2 diabetes, alongside HbA1c reductions of up to 2.0%. Published in The Lancet.[2]
• Liver fat reduction (MASLD): Sanyal et al. (2024) demonstrated that retatrutide reduced liver fat by up to 82.4% from baseline over 48 weeks, with 93% of participants achieving the ≥30% reduction threshold associated with MASLD resolution. Published in Nature Medicine.[3]
• Body composition: Coskun et al. (2025) published a body composition substudy showing retatrutide produced substantial fat mass reduction. Published in Lancet Diabetes & Endocrinology.[5]
• Meta-analysis confirmation: Pasqualotto et al. (2024) conducted a systematic review and meta-analysis confirming retatrutide’s weight and metabolic benefits across available trials.[4]

How Retatrutide Works

Retatrutide’s triple agonist mechanism is what distinguishes it from all currently approved obesity treatments. Each receptor contributes distinct pharmacological effects:[7][8][9]

• GLP-1 receptor activation: reduces appetite through central hypothalamic and brainstem signalling, slows gastric emptying, and enhances glucose-dependent insulin secretion. This is the shared mechanism with semaglutide and liraglutide.[7][9]
• GIP receptor activation: potentiates the GLP-1-mediated appetite reduction and insulin secretion, while potentially improving fat tissue metabolism. This is the shared mechanism with tirzepatide (which is a dual GIP/GLP-1 agonist).[7][8]
• Glucagon receptor activation (unique to retatrutide): this is the critical differentiator. Glucagon receptor agonism increases hepatic fat oxidation, stimulates thermogenesis and energy expenditure, promotes amino acid catabolism, and reduces liver fat. Unlike GLP-1 and GIP (which primarily reduce caloric intake), glucagon receptor activation increases caloric output.[7][8][9]

The engineering insight: retatrutide doesn’t just suppress appetite more effectively — it adds an entirely new metabolic dimension. The glucagon component creates a “push-pull” effect: GLP-1 and GIP reduce energy intake, while glucagon increases energy expenditure. This dual mechanism likely explains the unprecedented weight loss results and the dramatic liver fat reductions seen in the MASLD trial.[1][3][7]

Coskun et al. (2022) published the preclinical discovery and development of LY3437943 in Cell Metabolism, establishing the pharmacological rationale for the triple agonist approach and demonstrating superior weight loss and metabolic improvement versus dual agonism in preclinical models.[7]

Appetite and Weight Management Context

Appetite and weight management is where retatrutide has generated the most attention — and for good reason. The Phase 2 data represents a step-change in what pharmaceutical weight loss can achieve:[1]

• 24.2% mean weight loss at 48 weeks (12 mg dose) — unprecedented for any anti-obesity medication.[1]
• 100% of 12 mg participants lost ≥5% body weight; 83% lost ≥15%; 63% lost ≥20%.[1]
• Weight loss trajectory still descending at 48 weeks — the full plateau had not been reached, suggesting even greater reductions with longer treatment.[1]

For comparison within the incretin agonist class:

• Liraglutide (Saxenda): ~8% mean weight loss
• Semaglutide (Wegovy): ~15-17% mean weight loss
• Tirzepatide (Zepbound): ~20-22% mean weight loss
• Retatrutide: up to 24.2% mean weight loss — and still declining at study end

The honest caveat: these are Phase 2 results. Phase 3 trials (TRIUMPH) are underway and will provide the definitive efficacy and safety data needed for FDA approval. Phase 2 results don’t always replicate exactly in Phase 3, though the consistency across the obesity and T2D cohorts is encouraging. See Retatrutide vs Tirzepatide for the detailed comparison.[1][2][6]

Fat Loss and Body Recomp Context

Fat loss and body recomposition is where retatrutide’s triple agonist mechanism may offer a genuine advantage over dual and single agonists.

• Body composition data: Coskun et al. (2025) published a dedicated body composition substudy in Lancet Diabetes & Endocrinology, examining DEXA-measured changes in fat mass and lean mass with retatrutide in people with type 2 diabetes.[5]
• Glucagon-driven fat oxidation: the glucagon receptor component specifically promotes hepatic and systemic fat oxidation and thermogenesis — mechanisms that target fat mass reduction beyond what appetite suppression alone achieves.[7][8]
• Liver fat reduction: the Sanyal MASLD trial showed up to 82.4% liver fat reduction — a direct demonstration of the glucagon component’s effect on ectopic fat stores. This degree of hepatic fat clearance has not been achieved by any single or dual agonist.[3]

The lean mass question: like all GLP-1-class compounds, retatrutide-induced weight loss includes some lean mass component. Whether the glucagon receptor’s metabolic effects alter the fat-to-lean-mass loss ratio favourably compared to semaglutide or tirzepatide is being evaluated in Phase 3. Resistance exercise remains the most evidence-based strategy for preserving lean mass during pharmacological weight loss.

Metabolic Health and Insulin Sensitivity Context

Metabolic health and insulin sensitivity is retatrutide’s second major clinical domain, with particularly strong signals in liver health and glycaemic control.[2][3]

• Glycaemic control: Rosenstock et al. (2023) demonstrated HbA1c reductions of up to 2.0% in patients with type 2 diabetes — comparable to or exceeding other incretin-based therapies. Nearly all participants on higher doses achieved HbA1c targets.[2]
• MASLD/liver fat clearance: Sanyal et al. (2024) showed 82.4% liver fat reduction and 93% of participants meeting the ≥30% threshold associated with MASLD resolution. This is the strongest liver fat reduction data for any incretin-class compound — a direct result of the glucagon receptor component.[3]
• Insulin sensitivity improvement: the combination of substantial weight loss, visceral/hepatic fat reduction, and direct metabolic receptor activation produces multi-pathway insulin sensitivity improvement.[2][4]
• Cardiometabolic markers: systematic reviews have confirmed improvements across lipid profiles, blood pressure, and inflammatory markers alongside weight and glucose improvements.[4][10]

The liver health finding is clinically significant: MASLD/MASH (formerly NAFLD/NASH) affects approximately 30% of the global population and is becoming the leading cause of liver transplantation. A compound that can reduce liver fat by >80% while also addressing obesity and diabetes could represent a transformative treatment approach for overlapping cardiometabolic conditions.[3]

Retatrutide Benefits

Retatrutide benefits based on available Phase 2 evidence:

• Unprecedented weight loss magnitude: up to 24.2% mean body weight reduction at 48 weeks — the largest for any anti-obesity medication in controlled trials, and still declining at study end.[1]
• Triple receptor mechanism: unique glucagon receptor component adds energy expenditure and fat oxidation pathways beyond appetite suppression, targeting fat mass through both intake reduction and output increase.[7][8]
• Extraordinary liver fat reduction: up to 82.4% liver fat clearance in the MASLD trial — the strongest hepatic fat reduction of any incretin-class compound.[3]
• Robust glycaemic improvement: HbA1c reductions of up to 2.0% in patients with type 2 diabetes.[2]
• Once-weekly dosing: consistent with other modern incretin agonists, supporting treatment adherence.[1][2]
• Multi-indication potential: Phase 3 TRIUMPH programme spans obesity, T2D, OSA, and osteoarthritis — the broadest indication pipeline of any single incretin agonist.[6]
• Consistent efficacy across cohorts: weight loss and metabolic improvement demonstrated in both obesity and T2D populations, meta-analysis confirmed.[1][2][4]

Important framing: all current retatrutide benefits data is from Phase 2 trials. While the results are exceptionally promising, FDA approval and full safety characterisation require Phase 3 completion. The TRIUMPH programme is expected to report results over the coming years.[6]

Retatrutide Side Effects

For retatrutide side effects intent (search volume: 6,600), the safety profile is based on Phase 2 data with hundreds of participants, not yet the thousands typical of Phase 3:[1][2][11]

• Gastrointestinal effects (most common): nausea, diarrhoea, vomiting, and constipation — consistent with the GLP-1 receptor agonist class. In the NEJM Phase 2 trial, GI events were generally mild to moderate and most common during dose escalation. Incidence was dose-dependent.[1]
• Decreased appetite: reported frequently, though this is more of an intended pharmacological effect than a side effect per se.[1][2]
• Injection site reactions: generally mild.[1]
• Heart rate increase: small mean increases in heart rate observed, consistent with other GLP-1 agonists.[1][2]
• Glucagon-specific considerations: the glucagon receptor component theoretically increases hepatic glucose output, which could counteract the glucose-lowering effects in some contexts. In practice, the Phase 2 T2D trial showed net glycaemic improvement, suggesting the GLP-1/GIP components compensate effectively.[2][7]

What we don’t know yet:

• Long-term safety: the longest Phase 2 exposure is 48 weeks. Multi-year safety data will come from Phase 3 (TRIUMPH).[6]
• Cardiovascular outcomes: no dedicated CVOT has been completed for retatrutide. This will likely be required for full regulatory characterisation.
• Rare events: uncommon adverse events (pancreatitis, thyroid signals, gallbladder events) require larger Phase 3 populations to characterise properly.
• Glucagon receptor long-term effects: sustained glucagon receptor agonism is novel in this context. Any unexpected hepatic, metabolic, or body composition effects may only emerge with longer exposure.[8][9]

The honest assessment: the Phase 2 safety profile appears manageable and broadly consistent with the GLP-1 agonist class, but the compound is genuinely novel (no triple agonist has been approved before), and caution is warranted until Phase 3 data is available.[1][4][11]

Half-Life

Retatrutide has a plasma half-life of approximately 6 days, enabling once-weekly subcutaneous administration. This is comparable to other modern incretin agonists:[7]

• Liraglutide: ~13 hours (daily injection)
• Semaglutide: ~7 days (weekly injection)
• Tirzepatide: ~5 days (weekly injection)
• Retatrutide: ~6 days (weekly injection)

The ~6-day half-life provides sustained receptor activation across all three targets (GLP-1, GIP, glucagon) throughout the dosing interval, maintaining the coordinated metabolic effects between weekly injections.[7]

TRIUMPH Phase 3 Programme

The TRIUMPH clinical programme represents the most ambitious development plan for any single incretin agonist, spanning multiple obesity-related indications:[6]

• TRIUMPH-1: obesity without diabetes
• TRIUMPH-2: obesity with type 2 diabetes
• TRIUMPH-3: obesity with obstructive sleep apnoea
• TRIUMPH-4: obesity with knee osteoarthritis

Giblin et al. (2026) published the rationale and design of the TRIUMPH registration programme in Diabetes, Obesity and Metabolism, detailing the Phase 3 trial structures that will generate the data necessary for FDA approval decisions.[6]

Timeline context: if Phase 3 results are positive, retatrutide could potentially reach FDA approval in 2027-2028, though regulatory timelines are inherently uncertain. The breadth of the TRIUMPH programme reflects Eli Lilly’s confidence in the compound based on Phase 2 results.

Limits of Current Evidence

• No approved indication. Retatrutide is investigational. All clinical data comes from Phase 2 trials (hundreds of participants, not thousands). Phase 3 is underway but not yet reported.[1][6]
• No long-term safety data beyond 48 weeks. The longest exposure in published trials is 48 weeks. Multi-year safety characterisation requires Phase 3 completion.[1][2]
• No cardiovascular outcome trial. Unlike semaglutide (SELECT) and liraglutide (LEADER), retatrutide has no completed CVOT. This is a significant evidence gap for a compound targeting cardiometabolic populations.
• Novel mechanism, unknown unknowns. No triple GLP-1/GIP/glucagon agonist has been approved before. Sustained glucagon receptor activation in combination with incretin agonism is pharmacologically unprecedented, and unexpected effects may emerge with larger populations and longer exposure.[7][8]
• Cross-trial comparisons are indirect. Retatrutide has not been compared head-to-head with tirzepatide or semaglutide in a single trial. The “24% vs 22% vs 17%” weight loss framing compares across different trials with different populations and designs.[1]
• Phase 2 results may not fully replicate. Phase 3 trials have stricter inclusion criteria, larger populations, and longer follow-up. Results sometimes differ from Phase 2.

Decision rule: retatrutide’s Phase 2 data is the strongest of any anti-obesity medication at this development stage, published in the highest-quality journals (NEJM, Lancet, Nature Medicine). But it remains investigational, and the evidence gap between “promising Phase 2” and “approved with long-term safety data” is substantial.

Verdict

Retatrutide represents the most ambitious evolution of the incretin agonist class — the first triple GLP-1/GIP/glucagon receptor agonist with clinical data. Its Phase 2 results (24.2% weight loss, 82.4% liver fat reduction, 2.0% HbA1c improvement) are the strongest ever reported for any single anti-obesity compound in controlled trials.[1][2][3]

The glucagon receptor component is the key differentiator. It introduces energy expenditure and hepatic fat oxidation mechanisms that go beyond appetite suppression, creating a “reduce intake + increase output” approach that may explain the superior weight loss magnitude compared to dual agonists like tirzepatide.[7][8]

The critical caveat: retatrutide is not yet approved, has no long-term safety data, and the Phase 3 TRIUMPH programme must confirm these results before clinical use can be evaluated. The compound’s position in this guide is as the most promising investigational candidate in the incretin class — extraordinary Phase 2 evidence, but still investigational. See Retatrutide vs Tirzepatide for the detailed positioning against the current best-in-class approved dual agonist.

For navigation, map this profile to Appetite & Weight Management, Fat Loss & Recomp, and Metabolic Health / Insulin Sensitivity. Cross-reference with Tirzepatide, Semaglutide, and Liraglutide for full class context.

FAQ

What is retatrutide?

Retatrutide (LY3437943) is a first-in-class investigational triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, it produced the largest weight loss ever reported for any anti-obesity medication in Phase 2 trials (up to 24.2% at 48 weeks). It is currently in Phase 3 trials (TRIUMPH programme) but not yet FDA-approved.[1][6][7]

What does retatrutide do?

Retatrutide reduces appetite (via GLP-1/GIP receptors), improves glycaemic control (via GLP-1-mediated insulin secretion), and increases energy expenditure and fat oxidation (via glucagon receptor). Phase 2 trials demonstrated 24.2% body weight loss, 82.4% liver fat reduction, and HbA1c reductions of up to 2.0%.[1][2][3]

What are retatrutide side effects?

The most common side effects in Phase 2 trials were gastrointestinal: nausea, diarrhoea, vomiting, and constipation — consistent with the GLP-1 agonist class. These were generally mild to moderate and most common during dose escalation. Long-term safety data beyond 48 weeks is not yet available. Phase 3 will characterise rare events and the long-term effects of sustained glucagon receptor activation.[1][2]

Is retatrutide FDA approved?

No. Retatrutide is currently investigational and in Phase 3 clinical trials (the TRIUMPH programme). If Phase 3 results are positive, FDA approval could potentially occur around 2027-2028. It has not been approved for any indication in any country.[6]

How does retatrutide compare to tirzepatide?

Both are Eli Lilly compounds. Tirzepatide is a dual GIP/GLP-1 agonist (FDA-approved as Mounjaro/Zepbound); retatrutide adds a third target — the glucagon receptor. In cross-trial comparisons, retatrutide’s 24.2% weight loss exceeds tirzepatide’s ~20-22%, though no head-to-head trial exists yet. See Retatrutide vs Tirzepatide for the detailed comparison.[1][7]

How does retatrutide compare to semaglutide?

Semaglutide (Wegovy/Ozempic) is a single GLP-1 agonist producing ~15-17% weight loss. Retatrutide activates three receptors (GLP-1 + GIP + glucagon) and produced up to 24.2% weight loss in Phase 2. However, semaglutide is FDA-approved with extensive safety data including a cardiovascular outcomes trial (SELECT), while retatrutide remains investigational.[1]

Why is the glucagon receptor important?

Glucagon receptor activation increases hepatic fat oxidation, stimulates thermogenesis, and raises energy expenditure. This creates a “dual mechanism” for weight loss: GLP-1/GIP reduce caloric intake through appetite suppression, while glucagon increases caloric output through metabolic activation. This combination likely explains retatrutide’s superior weight loss and extraordinary liver fat reduction results.[3][7][8]

Retatrutide dose and retatrutide dosage: why not listed here?

This page is informational only and does not provide dosing protocols. Retatrutide is an investigational compound not approved for any indication. Phase 2 trials evaluated doses from 0.5 mg to 12 mg weekly. This profile focuses on mechanism context, evidence quality, and risk-aware interpretation.

How much weight can you lose on retatrutide?

In the Phase 2 NEJM trial, the highest dose (12 mg weekly) produced 24.2% mean body weight loss at 48 weeks. 83% of participants lost ≥15% and 63% lost ≥20%. The weight loss trajectory was still descending at 48 weeks, suggesting even greater losses with longer treatment. These are Phase 2 results; Phase 3 will provide definitive efficacy data.[1]

Does retatrutide help with fatty liver?

Yes — the Phase 2a MASLD trial (Sanyal 2024, Nature Medicine) showed up to 82.4% liver fat reduction from baseline, with 93% of participants meeting the clinically meaningful ≥30% threshold. This is the strongest liver fat reduction data for any incretin-class compound, likely driven by the glucagon receptor component’s direct effects on hepatic fat oxidation.[3]

When will retatrutide be available?

Retatrutide is in Phase 3 clinical trials (TRIUMPH programme). If results are positive and regulatory submission proceeds smoothly, approval could potentially occur around 2027-2028. Regulatory timelines are inherently uncertain and depend on Phase 3 results, safety data, and regulatory review processes.[6]

Is retatrutide safe?

Phase 2 data shows a safety profile broadly consistent with the GLP-1 agonist class (primarily GI side effects). However, long-term safety data beyond 48 weeks is not yet available, and the glucagon receptor component is pharmacologically novel. Phase 3 trials with larger populations and longer follow-up will provide the definitive safety characterisation. Caution is warranted for any investigational compound without full regulatory review.[1][2][6]

References

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315.
2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID: 37385280.
3. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(8):2292-2300. PMID: 38858523.
4. Pasqualotto E, et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabol Open. 2024;24:100313. PMID: 39318607.
5. Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2025;13(7):527-537. PMID: 40609566.
6. Giblin K, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registration programme. Diabetes Obes Metab. 2026;28(2):e70089. PMID: 41090431.
7. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PMID: 35985340.
8. Katsi V, et al. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(7):935. PMID: 40563436.
9. Abdul-Rahman T, et al. The power of three: Retatrutide’s role in modern obesity and diabetes therapy. Eur J Pharmacol. 2024;984:177068. PMID: 39515565.
10. Abdrabou Abouelmagd A, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis. Proc (Bayl Univ Med Cent). 2025;38(3):361-368. PMID: 40291085.
11. Kaur M, et al. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol. 2024;80(5):621-632. PMID: 38367045.